Participated · Series C · Aug 2025

Gameto develops stem cell-derived therapies for reproductive health, with its lead program Fertilo using iPSC-derived engineered ovarian support cells to mature eggs outside the body. Fertilo is cleared for commercialization in multiple ex-U.S. jurisdictions (Peru, Mexico, Australia, Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay) and has been used in clinics with five babies born and over 20 pregnancies recorded. The therapy shortens standard ovarian stimulation from about two weeks of daily hormone injections to 2–3 days and is the first iPSC-derived therapy to reach late-stage clinical development in the U.S. Gameto is conducting a randomized, controlled, double-blind Phase 3 trial (FIRST) at up to 20 U.S. sites with an anticipated interim readout in late 2026. Beyond Fertilo, the company is developing the ARPA-H-funded Ameno menopause program, which includes an implantable cell therapy and a next-generation vaginal ring planned for Phase 1. Gameto's platform is built on an AI-powered in vitro organoid system developed with George Church's lab, and the company has raised $127 million to date. Gameto develops Fertilo, a novel investigational in vitro maturation (IVM) solution that uses engineered ovarian support cells (OSCs) to mature eggs outside the body. The company aims to make IVF and egg freezing shorter, safer, and more accessible by reducing hormonal injections. Gameto is led by CEO Dr. Dina Radenkovic and is already using Fertilo in clinical settings in Australia and Latin America. Following discussions with the U.S. Food and Drug Administration, Gameto received tentative approval to proceed to Phase 3 trials subject to completion of certain assay and manufacturing requirements. The recent financing will support clinical development of Fertilo and continued commercial launches in markets where it is in use. Financially, the company reported a $33M Series B that brought total funding to $73M. Gameto is a biotechnology company using cell engineering to develop therapeutics for diseases of the female reproductive system. Its underlying cell‑engineering platform was developed in stealth under a scientific research agreement with George Church’s lab at Harvard Medical School. The company is led by Dr. Dina Radenkovic and operates out of New York City and Madrid. In January it announced three sequenced programs: Fertilo (a biologic for IVF and egg freezing), Deovo (an organoid of the female reproductive system), and Ameno (a cell‑based therapeutic for primary ovarian insufficiency and menopause). Fertilo has entered preclinical development in partnership with clinics in the US and Spain, and partner clinics named include Extend Fertility, RMA, Pozitivf, Ovation Fertility, Clinica Tambre, and Hospital Ruber Internacional. Gameto intends to use the new funding to expand operations and broaden its business reach. Gameto is developing a platform for ovarian therapeutics that targets accelerated ovarian aging to change the trajectory of women’s health and equality. Its initial focus is on addressing menopause and improving assisted fertility through three sequenced programs: Fertilo, Deovo and Ameno. Fertilo aims to improve assisted fertility with a long-term mission to eliminate infertility; Deovo is initiating drug discovery and a computational platform for ovarian aging; Ameno aims to make the medical burden of menopause optional. The company is led by CEO Dr. Dina Radenkovic with Martin Varsavsky as chairman and is based in New York City and Boston, Massachusetts. Financially, Gameto disclosed a $20M Series A and a prior $3M seed (March 2020), totaling $23M in disclosed funding.